Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594067 · ClinicalTrials.gov registry record · Phase 1
TCR1188-ABC Cells in KRAS-mutated Cancers
A Phase 1 study, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07594067: Recruiting Phase 1 study, sponsored by University of Pennsylvania.
NCT07594067 is a Phase 1 study that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07594067, a Phase 1 study, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Interventions
- DRUG Tocilizumab
- DRUG Fludarabine + Cyclophosphamide combination
- BIOLOGICAL TCR1188-ABC cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07 |
| Est. Completion | 2042-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07594067
The ClinicalTrials.gov registry entry for NCT07594067 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tocilizumab is the first listed.
NCT07594067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07594067 about?
NCT07594067 is a clinical study titled "TCR1188-ABC Cells in KRAS-mutated Cancers". This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colore...
What is the current status of trial NCT07594067?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07. Estimated completion is 2042-07.
What interventions are being tested in trial NCT07594067?
The interventions under investigation include: Tocilizumab (DRUG), Fludarabine + Cyclophosphamide combination (DRUG), TCR1188-ABC cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07594067?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.